Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 7;9(12):10317-10323.
doi: 10.18632/oncotarget.23126. eCollection 2018 Feb 13.

Circulating microRNA-196a is an early gastric cancer biomarker

Tsung-Hsing Chen  1   2 , Chieh Lee  3 , Cheng-Tang Chiu  1 , Yin-Yi Chu  1 , Hao-Tsai Cheng  1 , Jun-Te Hsu  4 , Yung-Kuan Tsou  1 , Ren-Chin Wu  5 , Tse-Ching Chen  5 , Nien-Chen Chang  6 , Ta-Sen Yeh  4 , Kwang-Huei Lin  6   7   8
Affiliations

Circulating microRNA-196a is an early gastric cancer biomarker

Tsung-Hsing Chen et al. Oncotarget. .

Abstract

MicroRNA-196a (miRNA-196a) is associated with the development of gastric cancer and metastasis. Intestinal metaplasia and low- or high-grade dysplasia are considered to be precursors of intestinal type gastric cancer. Accordingly, we investigated the expression of plasma miRNA-196a as an early detection biomarker in precancerous gastric lesions and early cancer (pT1a/b), which is otherwise treated with endoscopic submucosal dissection. Our data showed that levels of circulating (plasma) miRNA-196a were higher in patients with precancerous lesions/early gastric adenocarcinoma than in healthy controls. The area under the receiver operating characteristic curve (AUC) for healthy controls vs. intestinal metaplasia was 0.9736; healthy controls vs. low-grade/high-grade dysplasia 0.9495; and healthy controls vs. early gastric cancer 0.9318. These results indicate that circulating miRNA-196a is a novel biomarker for detection of early gastric cancer and its precursor.

Keywords: dysplasia; early gastric cancer; intestinal metaplasia; microRNA-196a; precancerous gastric lesions.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicting financial interests.

Figures

Figure 1
Figure 1. Normality test for healthy volunteers and boxplots of expression of miRNA196a in plasma. ***P-value < 0.001 **P-value < 0.01
(A) Normality Test for Healthy Control. (B) Boxplots of Expression of miRNA-196a in Plasma for healthy donor (control), all stages of percancer and early cancer. (C) Boxplots of Expression of miRNA-196a in Plasma for healthy control, percancer, and early cancer. IM: intestinal metaplasia; LG: low-grade dysplasia; HG: high-grade dysplasia; EC: early cancer.
Figure 2
Figure 2. ROC curves for each phase
(A) ROC curve of healthy subjects vs. IM, HGD, and LGD; AUC was 0.9655. (B) ROC curve of healthy subjects vs. IM; AUC was 0.9736. (C) ROC curve of healthy subjects vs. LGD and HGD; AUC was 0.9495. (D) ROC curve of healthy subjects vs. EC; AUC was 0.9318. IM: intestinal metaplasia; LGD: low-grade dysplasia; HGD: high-grade dysplasia; EC: early cancer.
Figure 3
Figure 3. ROC curves for each phase
(A) ROC curve of IM vs. EC; AUC was 0.7184. (B) ROC curve of LGD/HGD, vs. EC; AUC was 0.7196 IM: intestinal metaplasia; LGD: low-grade dysplasia; HGD: high-grade dysplasia; EC: early cancer.
See this image and copyright information in PMC

References

    1. Green D, Ponce de Leon S, Leon-Rodriguez E, Sosa-Sanchez R. Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol. 2002;25:84–89. https://doi.org/10.1097/00000421-200202000-00018 - DOI - PubMed
    1. Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer. 2000;36:390–396. https://doi.org/10.1016/S0959-8049(99)00308-1 - DOI - PubMed
    1. Harrison LE, Karpeh MS, Brennan MF. Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. J Gastrointest Surg. 1998;2:126–131. https://doi.org/10.1016/S1091-255X(98)80002-4 - DOI - PubMed
    1. Craanen ME, Dekker W, Ferwerda J, Blok P, Tytgat GN. Early gastric cancer: a clinicopathologic study. J Clin Gastroenterol. 1991;13:274–283. https://doi.org/10.1097/00004836-199106000-00006 - DOI - PubMed
    1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–6740. - PubMed

LinkOut - more resources